Models
1
Overview
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California , specializing in tissue heart valves and transcatheter technologies for structural heart disease. Founded by Miles Lowell Edwards in 1958, the company invented the first successful artificial heart valve (the Starr-Edwards valve) and pioneered transcatheter aortic valve replacement (TAVR) with its SAPIEN 3 platform. The company is listed on the NYSE (EW) and is an S&P 500 component.
Verified record
- Verified deployments
- None on file
- Active incidents
- 1 incident on file
DEPLOY Intelligence
Market intelligence for physical AI
Analyst-grade signals, competitive tracking, and investment context across the global physical AI landscape. Launching 2026.
Key facts
CEO
Previous CEO
Founder
NYSE Ticker
S&P 500 Component
Key Product
Manufacturing
Parent Company History
Revenue 2025
Employees
Data & sources
Web sources
1
1 source backing this record.View all →
Models (1)
View all models →Current leadership (3)
- Bernard J. Zovighian CEOreported, not verified
- Michael Mussallem Former Chairman & CEOreported, not verified
- Miles Lowell Edwards Founderreported, not verified
Founders (1)
- Miles Lowell Edwardscofounderno longer at company
Safety record
Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.
Full safety record: incidents, sourcing, and exposure data →
Incidents affecting Edwards Lifesciences (1)
Includes incidents linked directly to this company, to its models, or to deployments of its models or under its operation. Retracted incidents are excluded from this view but remain reachable at their canonical URLs.
Recent coverage
Edwards Lifesciences in third-party press
Peer companies
- Johnson & Johnson3 models
- Intuitive Surgical2 models
- LEM Surgical2 models
- MicroPort MedBot2 models
- Neocis2 models
- Stryker2 models
Financial state
- Reporting basis
- sec_10k
- Lifecycle stage
- mature
- Counterparty risk class
- low
Each numeric field carries its own basis marker. Aggregators report a number; this surface preserves the source class so verification depth travels with the value.
Recent activity
Every change to this record is dated, sourced, and independently verified where marked.
- Record createdJun 8, 2026
Added to the verified registry
- Incident recordedMay 16, 2025
FDA Class I recall of Edwards Lifesciences arterial cannulae due to risk of wire exposure
Sources (1)
Common questions
- What is Edwards Lifesciences?
- Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in tissue heart valves and transcatheter technologies for structural heart disease. Founded by Miles Lowell Edwards in 1958, the company invented the first successful artificial heart valve (the Starr-Edwards valve) and pioneered transcatheter aortic valve replacement (TAVR) with its SAPIEN 3 platform. The company is listed on the NYSE (EW) and is an S&P 500 component.
- What does Edwards Lifesciences make?
- Edwards Lifesciences has 1 robot model on the DEPLOY registry: SAPIEN 3 Transcatheter Heart Valve (Edwards Lifesciences builds both physical robots and the AI that runs them).
- Is Edwards Lifesciences publicly traded?
- Edwards Lifesciences is not independently listed on public markets; it is part of Baxter International 1985 on the DEPLOY registry.
- Who competes with Edwards Lifesciences?
- On the DEPLOY registry, peer companies to Edwards Lifesciences building in the same form factors include Johnson & Johnson, Intuitive Surgical, LEM Surgical, MicroPort MedBot.
- Who is the CEO of Edwards Lifesciences?
- Bernard J. Zovighian is the ceo of Edwards Lifesciences, per the DEPLOY registry.
- How can I invest in Edwards Lifesciences?
- Edwards Lifesciences has no separately traded stock; it is owned by Baxter International 1985 (the parent is the entity that trades, where it is public).
- Where is Edwards Lifesciences headquartered?
- Edwards Lifesciences is headquartered in Irvine, California, USA.
- Who owns Edwards Lifesciences?
- Edwards Lifesciences is owned by Baxter International 1985, per the DEPLOY registry.
- Where does Edwards Lifesciences operate robots?
- Edwards Lifesciences is a robot manufacturer and does not directly operate deployments on the DEPLOY registry. Its products are deployed by customer operators; see the company page for the verified deployment record.
- Is Edwards Lifesciences a top robotics company?
- On DEPLOY's intelligence score, which blends verified deployments, funding, hiring, media, safety, and IP signals, Edwards Lifesciences ranks in roughly the top 18% of companies tracked by the registry.
- Are there any incidents involving Edwards Lifesciences?
- 1 active incident involving Edwards Lifesciences is on the DEPLOY registry. Each is a sourced, append-only record; retracted incidents are suppressed from this view.
- Is Edwards Lifesciences safe?
- Edwards Lifesciences has 1 active incident on record in the DEPLOY registry. 1 recall on record (1 serious). Most recent: May 2025. Retracted incidents are excluded from this count.
Methodology: Verified · 1 source (no primary) · last reviewed 2026-07-07
Verification posture
Verified
Low confidence
Review state
Stable
Last reviewed 2026-07-07
Sources by quality tier
- 1
- unclassified
- Unclassified source
The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.
Methodology surface for Edwards Lifesciences.Peer companies
- Johnson & Johnson3 models
- Intuitive Surgical2 models
- LEM Surgical2 models
- MicroPort MedBot2 models
- Neocis2 models
- Stryker2 models
In the press
Recent coverage mentioning Edwards Lifesciences from third-party publications. Automatically surfaced; not part of the verified registry record.
CMS Proposes TAVR Medicare Coverage is Potential Boost for Edwards Lifesciences
CMS’s proposed expansion of Medicare TAVR coverage to include select asymptomatic severe aortic stenosis patients and reduce access barriers for symptomatic patients could…
FTC Challenges Anticompetitive Medical Device Deal
The FTC challenged Edwards Lifesciences' acquisition of JenaValve, alleging it would disrupt competition for revolutionary heart condition devices.
FDA: Edwards Lifesciences Removes Arterial Cannula due to Risk of Wire Exposure
FDA issued a Class I recall for Edwards Lifesciences OptiSite Arterial Perfusion Cannula and Peripheral Femoral Arterial Cannula models due to risk of wire exposure that could…
Edwards Lifesciences Reports Fourth Quarter Results
Edwards Lifesciences reported Q4 and full-year 2025 financial results, with revenue of US.07 billion.
Edwards Lifesciences chair Michael Mussallem retires from board
Michael Mussallem retired from the Edwards Lifesciences board after 23 years as CEO and chair, having led the company since its 2000 IPO spin-off from Baxter.
Machine-readable surfaces
- Markdown mirror: /companies/edwards-lifesciences.md
- RSS feed: /companies/edwards-lifesciences/feed.xml
- JSON-LD: embedded in this page’s head
- REST API: /v1/companies/311e9cc4-68db-4d74-b74c-33fd30682fc4
- Revision history: /companies/edwards-lifesciences/history
- Data documentation: /data
- Query this programmatically: Deploy MCP
Peer companies
- Johnson & Johnson3 models
- Intuitive Surgical2 models
- LEM Surgical2 models
- MicroPort MedBot2 models
- Neocis2 models
- Stryker2 models
Video
How the EVOQUE valve is implanted via the transfemoral approach: A step-by-step illustration of tricuspid valve replacement with the EVOQUE Tricuspid Valve Replacement System. Content related to Edwards Lifesciences de
In 1958, Miles “Lowell” Edwards set out to build an artificial heart. But like so many other great inventors, Edwards and his trusted partner, Dr. Albert Starr,
Cutting-edge medical science helped Edwards Lifesciences' stock stay healthy so far in 2017, with a rise of over 25% year to date. Could it continue to head hig
Edwards Lifesciences CEO Michael Mussallem tells CNBC's Jim Cramer that the medical equipment company has prioritized improving care for structural heart diseas
Discover the challenges and requirements for the effective treatment of tricuspid valve disease. A global panel of experts draws upon multi-centre, real-world e
Driven by a passion to help, Edwards Lifesciences collaborates with the world’s leading clinicians and researchers, working to improve outcomes and enhance live
There are many different pathways students can take to be involved in medical innovation and entrepreneurship. Hear from a variety of industry professionals as
In this episode, Gary speaks with Michael A. Mussallem, Chairman and CEO, Edwards Lifesciences. They spoke about the future of healthcare technology and innovat
Rick, a farmer from Canada, has been hardworking his entire life. As a child, he was sick with rheumatic fever, which left his heart valves damaged and caused h
Reality vs attention
Edwards Lifesciences draws attention at the 58th percentile but verifies reality at the insufficient-data level among surgical robots.
6-month trend
Analysis
Safety profile within acceptable range for category. Limited public funding data for capital position assessment.
Signal flags
Dimension breakdown
Verified signal
Attention (reach, not merit)
DEPLOY Intelligence scores are computed from verified registry data: confirmed deployments, disclosed funding rounds, regulatory filings, active job listings, video viewership, and press coverage. Confidence ratings reflect data availability. Scores update nightly.
DEPLOY Indices — verified vs claimed
Last computed: Jul 19, 2026